cyclophosphamide + doxorubicin + vincristine + prednisone + chidamide + tislelizumab

This is a multi-agent combination regimen consisting of six drugs: - Cyclophosphamide (an alkylating agent) - Doxorubicin (an anthracycline antibiotic) - Vincristine (a vinca alkaloid) - Prednisone (a synthetic glucocorticoid corticosteroid) - Chidamide (a histone deacetylase inhibitor, HDACi) - Tislelizumab (a monoclonal antibody targeting PD-1) The first four agents form the classic CHOP chemotherapy backbone, widely used for lymphomas. Cyclophosphamide crosslinks DNA to inhibit cell division; doxorubicin intercalates DNA and inhibits topoisomerase II; vincristine disrupts microtubule formation; prednisone induces apoptosis in certain cancer cells and modulates immune response[2][4][8]. Chidamide is an epigenetic modulator that inhibits histone deacetylases, leading to altered gene expression and apoptosis in malignant cells. Tislelizumab is an immune checkpoint inhibitor that blocks PD-1 on T-cells, enhancing anti-tumor immunity. This combination represents a novel approach integrating cytotoxic chemotherapy, epigenetic modulation, and immunotherapy. It may be under investigation for aggressive or refractory lymphomas or other hematologic malignancies where standard regimens are insufficient.